Cryosite Ltd
ASX:CTE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.55
1.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cryosite Ltd
Cryosite Ltd
Cash & Cash Equivalents
Cryosite Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cryosite Ltd
ASX:CTE
|
Cash & Cash Equivalents
AU$703k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
3%
|
|
|
Anteotech Ltd
ASX:ADO
|
Cash & Cash Equivalents
AU$5m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Cash & Cash Equivalents
AU$6.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Cash & Cash Equivalents
AU$11.2m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Genetic Signatures Ltd
ASX:GSS
|
Cash & Cash Equivalents
AU$36.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Cash & Cash Equivalents
AU$19m
|
CAGR 3-Years
29%
|
CAGR 5-Years
115%
|
CAGR 10-Years
N/A
|
|
Cryosite Ltd
Glance View
Cryosite Ltd. engages in the provision of long term storage, supply chain logistics management of pharmaceutical products used in clinical trials and biological materials. The company is headquartered in Sydney, New South Wales. The company went IPO on 2002-05-09. The firm operates through two segments, which include Clinical Trials and Biological Services Logistics, and Cord Blood and Tissue Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services to the clinical trial and research industry. The Cord Blood and Tissue Storage segment provides long-term storage for cord blood and tissue samples. The firm engages in clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution, and reverse logistics management.
See Also
What is Cryosite Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
703k
AUD
Based on the financial report for Jun 30, 2024, Cryosite Ltd's Cash & Cash Equivalents amounts to 703k AUD.
What is Cryosite Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
3%
Over the last year, the Cash & Cash Equivalents growth was -88%. The average annual Cash & Cash Equivalents growth rates for Cryosite Ltd have been -43% over the past three years , -29% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet
